Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Asset Writedowns and Impairment (2016 - 2026)

Champions Oncology has reported Asset Writedowns and Impairment over the past 8 years, most recently at -$30000.0 for Q1 2026.

  • Quarterly results put Asset Writedowns and Impairment at -$30000.0 for Q1 2026, up 25.0% from a year ago — trailing twelve months through Jan 2026 was $2000.0 (up 101.27% YoY), and the annual figure for FY2025 was -$272000.0, down 157.14%.
  • Asset Writedowns and Impairment for Q1 2026 was -$30000.0 at Champions Oncology, down from $13000.0 in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for CSBR hit a ceiling of $724000.0 in Q2 2023 and a floor of -$209000.0 in Q4 2024.
  • Median Asset Writedowns and Impairment over the past 5 years was $30500.0 (2025), compared with a mean of $68928.6.
  • Peak annual rise in Asset Writedowns and Impairment hit 270.21% in 2024, while the deepest fall reached 390.28% in 2024.
  • Champions Oncology's Asset Writedowns and Impairment stood at $130000.0 in 2022, then crashed by 44.62% to $72000.0 in 2023, then crashed by 390.28% to -$209000.0 in 2024, then soared by 106.22% to $13000.0 in 2025, then plummeted by 330.77% to -$30000.0 in 2026.
  • The last three reported values for Asset Writedowns and Impairment were -$30000.0 (Q1 2026), $13000.0 (Q4 2025), and -$29000.0 (Q3 2025) per Business Quant data.